Get the Stockscreener App
0.4441
0.07%
-0.0003
Pre-market:
.47
0.0259
+5.83%
Dyadic International Inc De stock is traded at $0.4441, with a volume of 12,973.
It is down -0.07% in the last 24 hours and down -8.24% over the past month.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
See More
Previous Close:
$0.4444
Open:
$0.4518
24h Volume:
12,973
Relative Volume:
0.11
Market Cap:
$17.79M
Revenue:
$3.81M
Net Income/Loss:
$-7.29M
P/E Ratio:
-2.0762
EPS:
-0.2139
Net Cash Flow:
$-5.72M
1W Performance:
-2.18%
1M Performance:
-8.24%
6M Performance:
-50.15%
1Y Performance:
-57.70%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.4384
$0.489
52-Week Range:
$0.3401
$1.60
Dyadic International Inc De Stock (DYAI) Company Profile
Name
Dyadic International Inc De
Sector
Industry
Phone
561-743-8333
Address
1044 NORTH U.S. HIGHWAY ONE, JUPITER
Compare DYAI vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYAI
Dyadic International Inc De
|
0.4441 | 17.79M | 3.81M | -7.29M | -5.72M | -0.2139 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dyadic International Inc De Stock (DYAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-23-25 | Resumed | H.C. Wainwright | Buy |
| Sep-08-25 | Initiated | Craig Hallum | Buy |
| Jul-18-22 | Downgrade | Dawson James | Buy → Neutral |
| Dec-17-21 | Initiated | H.C. Wainwright | Buy |
Dyadic International Inc De Stock (DYAI) Latest News
Dyadic International stock faces two Nasdaq compliance tests - AD HOC NEWS
Dyadic International stock faces two Nasdaq compliance tests - AD HOC NEWS
Dyadic International (Nasdaq:DYAI)Stock Analysis - Simply Wall Street
Dyadic International Faces Nasdaq Listing Compliance Challenges - The Globe and Mail
Form 8K Dyadic International Inc For: 25 September By Investing.com - Investing.com Nigeria
Dyadic International Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Dyadic gets Nasdaq notices over $1, $35M rules - Stock Titan
Dyadic International stock rises 2.5 percent as warrants add risk - AD HOC NEWS
Dyadic International stock trades without a fresh market catalyst - AD HOC NEWS
Dyadic International stock edges higher as S-1 registration becomes effective - AD HOC NEWS
DYADIC INTERNATIONAL INC SEC Filing (Sep 21, 2026) - Stock Titan
Emerging Growth Patterns Driving Rapid Expansion in the Protein Hydrolysis Enzymes Market - openPR.com
iAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026 - Finviz
Dyadic International (Nasdaq: DYAI) Advances Protein Manufacturing Platforms with Global Health Research Support - usatoday.com
Imperium AI Announces Board Discussion Regarding Dyadic Biotechnology Developments - usatoday.com
Dyadic International (Nasdaq: DYAI) Advances Next-Generation Biomanufacturing With Global Health Support to Help Turn AI-Designed DNA Into Life-Saving Products - StreetInsider
Dyadic International (DYAI) Q2 2026 Earnings Call Transcript - AOL.ca
Amylase Enzyme Cleaner Market Growth to 2035 Driven by Membrane Filtration DemandNews and Statistics - IndexBox
Llamada de resultados del T2 de 2026 de Dyadic International (DYAI): progreso comercial y riesgo de liquidez - TradingKey
Dyadic International Announces New Equity Financing Agreements - TipRanks
Dyadic International (DYAI) Ergebniskonferenz Q2 2026: Kommerzielle Fortschritte und Liquiditätsrisiko - TradingKey
Dyadic International (NASDAQ: DYAI) prices $2.9M stock sale and warrant placement - Stock Titan
Dyadic International Earnings Call: Promise Amid Cash Strain - TipRanks
Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement - GlobeNewswire
Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement - GlobeNewswire
Dyadic International, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Dyadic raises $2.9 million in registered direct offering - Investing.com
Dyadic International Warns of Going-Concern Risk as Dilution, Nasdaq Uncertainty and Noteholder Dependence Threaten Shareholder Value - TipRanks
Dyadic International Q2 Results: EPS Misses Estimate, Sales Down 0.6% YoY - scanx.trade
Dyadic Announces Second Quarter 2026 Financial Results - GlobeNewswire
Dyadic reports Q2 loss amid commercialization efforts - Investing.com
Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas - Yahoo Finance
Dyadic International Inc (DYAI) (Q2 2026) Earnings Call Highlights: Revenue Surges 52% as ... - Yahoo Finance
Earnings To Watch: Dyadic International Inc (DYAI) Q2 2026 -- GF Value Sees 40% Downside - Yahoo Finance
Cellulase Silage Additives Market Growth to 2035 Driven by Asia-Pacific Livestock ExpansionNews and Statistics - IndexBox
Segmentation, Major Trends, and Competitive Overview of the Specialty Enzymes Market - openPR.com
Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement - GlobeNewswire
Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement - GlobeNewswire
Dyadic signs license deal for precision-fermented dairy proteins - Investing.com
Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026 - GlobeNewswire
Dyadic Delivers Two Bundibugyo Ebola Antigens for Preclinical Evaluation - Stock Titan
Form 4 Dyadic International Inc For: 25 July By Investing.com - Investing.com South Africa
Form 4 Dyadic International Inc For: 25 July By Investing.com - Investing.com Canada
Francisco trust disposes of $124,957 in Dyadic International stock By Investing.com - Investing.com Canada
Dyadic Regains Nasdaq Compliance, Secures Continued Listing - TipRanks
Dyadic regains compliance with Nasdaq listing requirements By Investing.com - Investing.com Canada
Dyadic International, Inc. (DYAI) stock price, news, quote and history - Yahoo Finance Singapore
Dyadic Announces Continued Listing on the Nasdaq Capital Market - GlobeNewswire
Dyadic Announces Continued Listing on the Nasdaq Capital Market - GlobeNewswire
Dyadic regains compliance with Nasdaq listing requirements - Investing.com
Dyadic International Inc De Stock (DYAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dyadic International Inc De Stock (DYAI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Francisco Trust under agreemen | 10% Owner |
Jul 24 '26 |
Sale |
1.21 |
2,616 |
3,173 |
3,280,272 |
| Francisco Trust under agreemen | 10% Owner |
Jul 22 '26 |
Sale |
1.33 |
38,016 |
50,481 |
3,337,648 |
| Francisco Trust under agreemen | Greater than 10% holder |
Jul 21 '26 |
Proposed Sale |
1.48 |
364,387 |
539,296 |
0 |
1.64%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):